Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk

Dow Jones13:25 ET

Astellas Receives Complete Response Letter From FDA for Izervay SNDA

Seeking AlphaNov 19 09:09 ET

Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57

Moomoo NewsNov 19 08:32 ET · Ratings

Apellis Pharmaceuticals (APLS) Receives a Buy From Jefferies

TipRanksNov 19 07:56 ET · Ratings

Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $32

Moomoo NewsNov 19 07:33 ET · Ratings

Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)

TipRanksNov 19 06:47 ET · Ratings